ArriVent BioPharma (NASDAQ:AVBP) Downgraded by Wall Street Zen to "Strong Sell"

Key Points

• Wall Street Zen downgraded ArriVent BioPharma to “Strong Sell” from “Sell,” adding to recent concerns about the stock.
• Analyst sentiment remains mixed: BTIG, Truist, Jefferies and Citigroup maintain or set “Buy” ratings, while the consensus is “Moderate Buy” with a $27.44 target price.
• AVBP opened at $16.73, well below its 52-week high of $35.83, and recently reported an adjusted loss of $1.05 per share versus the expected $0.99 loss.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Saturday, Wall Street Zen reports.

AVBP has been the topic of a number of other research reports. BTIG Research cut their price target on shares of ArriVent BioPharma from $42.00 to $29.00 and set a "buy" rating on the stock in a research note on Wednesday. Truist Financial lowered their price objective on shares of ArriVent BioPharma from $45.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday. Weiss Ratings reissued a "sell (d-)" rating on shares of ArriVent BioPharma in a report on Friday, July 17th. Jefferies Financial Group set a $18.00 price objective on shares of ArriVent BioPharma in a report on Tuesday. Finally, Citigroup cut their target price on ArriVent BioPharma from $40.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ArriVent BioPharma currently has an average rating of "Moderate Buy" and a consensus target price of $27.44.

ArriVent BioPharma Stock Performance

Shares of AVBP stock opened at $16.73 on Friday. ArriVent BioPharma has a fifty-two week low of $11.36 and a fifty-two week high of $35.83. The firm has a market capitalization of $824.92 million, a price-to-earnings ratio of -4.62 and a beta of 1.34. The stock's 50-day simple moving average is $28.76 and its 200-day simple moving average is $29.26.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.06). As a group, equities analysts forecast that ArriVent BioPharma will post -4.11 earnings per share for the current year.

Institutional Trading of ArriVent BioPharma

Several hedge funds and other institutional investors have recently bought and sold shares of AVBP. Montanova Capital LLC boosted its holdings in ArriVent BioPharma by 2.6% during the second quarter. Montanova Capital LLC now owns 4,515,531 shares of the company's stock worth $156,870,000 after buying an additional 114,448 shares in the last quarter. Hhlr Advisors LTD. purchased a new position in ArriVent BioPharma in the second quarter valued at $136,498,000. BlackRock Inc. purchased a new position in ArriVent BioPharma in the second quarter valued at $112,919,000. General Catalyst Group Management LLC acquired a new position in shares of ArriVent BioPharma in the second quarter worth about $51,929,000. Finally, Vivo Capital LLC acquired a new position in shares of ArriVent BioPharma in the first quarter worth about $20,438,000. 9.48% of the stock is owned by institutional investors and hedge funds.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent's lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.